Leveraging Diagnostics in a Biotech World
Executive SummaryCorixa's recent deal with Ortho-Clinical Diagnostics brings Ortho exclusive worldwide diagnostics rights to Corixa's breast cancer genes and antigens and helps Ortho gain a foothold in the emerging area of molecular testing. It also illustrates how biotech companies caught up in long-term programs for therapeutics can capture some near-term value. While Corixa's lead drug is delayed at the FDA, the deal gives the company a source of revenues that may be small but is at least real.
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.